Alectinib-d8

Alectinib-d8 is the deuterium labeled Alectinib. Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively[1]. Alectinib demonstrates effective central nervous system (CNS) penetration[2].

Product Specifications

CAS Number

1256585-15-5

Product Name Alternative

CH5424802-d8; RO5424802-d8; AF802-d8

UNSPSC

12352005

Target

Anaplastic lymphoma kinase (ALK) ; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Others; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Solubility

10 mM in DMSO

Smiles

N#CC1=CC2=C(C3=C(N2)C(C)(C4=CC(N5CCC(CC5)N6C([2H])([2H])C([2H])([2H])OC([2H])([2H])C6([2H])[2H])=C(C=C4C3=O)CC)C)C=C1

Molecular Formula

C30H26D8N4O2

Molecular Weight

490.67

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Sakamoto H, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011, 19 (5), 679-690.|[3]Gadgeel S, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018 Nov 1;29 (11) :2214-2222.